|
1
|
Ahmadzadeh M, Johnson LA, Heemskerk B,
Wunderlich JR, Dudley ME, White DE and Rosenberg SA: Tumor
antigen-specific CD8 T cells infiltrating the tumor express high
levels of PD-1 and are functionally impaired. Blood. 114:1537–1544.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prosser ME, Brown CE, Shami AF, Forman SJ
and Jensen MC: Tumor PD-L1 co-stimulates primary human CD8(+)
cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Mol Immunol. 51:263–272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
June CH, Ledbetter JA, Linsley PS and
Thompson CB: Role of the CD28 receptor in T-cell activation.
Immunol Today. 11:211–216. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alvarez-Vallina L and Hawkins RE:
Antigen-specific targeting of CD28-mediated T cell co-stimulation
using chimeric single-chain antibody variable fragment-CD28
receptors. Eur J Immunol. 26:2304–2309. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Louis-Dit-Sully C, Blumenthal B,
Duchniewicz M, Beck-Garcia K, Fiala GJ, Beck-García E, Mukenhirn M,
Minguet S and Schamel WW: Activation of the TCR complex by
peptide-MHC and superantigens. Exs. 104:9–23. 2014.PubMed/NCBI
|
|
6
|
Salazar-Fontana LI, Barr V, Samelson LE
and Bierer BE: CD28 engagement promotes actin polymerization
through the activation of the small Rho GTPase Cdc42 in human T
cells. J Immunol. 171:2225–2232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Passardi A, Canale M, Valgiusti M and
Ulivi P: Immune checkpoints as a target for colorectal cancer
treatment. Int J Mol Sci. 18(pii): E13242017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Saad FT, Hincal E and Kaymakamzade B:
Dynamics of immune checkpoints, immune system, and BCG in the
treatment of superficial bladder cancer. Comput Math Methods Med.
2017:35730822017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma P and Allison JP: Immune checkpoint
targeting in cancer therapy: Toward combination strategies with
curative potential. Cell. 161:205–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beatty GL and Gladney WL: Immune Escape
Mechanisms as a Guide for Cancer Immunotherapy. Clin Cancer Res.
21:687–692. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janssen LME, Ramsay EE, Logsdon CD and
Overwijk WW: The immune system in cancer metastasis: Friend or foe?
J Immunother Cancer. 5:792017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartelt RR, Cruz-Orcutt N, Collins M and
Houtman JC: Comparison of T cell receptor-induced proximal
signaling and downstream functions in immortalized and primary T
cells. PLoS One. 4:e54302009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thaker YR, Schneider H and Rudd CE: TCR
and CD28 activate the transcription factor NF-κB in T-cells via
distinct adaptor signaling complexes. Immunol Lett. 163:113–119.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Latchman Y, Wood C, Chemova T, Chaudhary
D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al:
PD-L2, a novel B7 homologue, is a second ligand for PD-1 and
inhibits T cell activation. Nat Immunol. 15:261–268. 2001.
View Article : Google Scholar
|
|
17
|
Kim HR, Ha SJ, Hong MH, Heo SJ, Koh YW,
Choi EC, Kim EK, Pyo KH, Jung I, Seo D, et al: PD-L1 expression on
immune cells, but not on tumor cells, is a favorable prognostic
factor for head and neck cancer patients. Sci Rep. 6:369562016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Keir ME, Liang SC, Guleria I, Latchman YE,
Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH and Sharpe
AH: Tissue expression of PD-L1 mediates peripheral T cell
tolerance. J Exp Med. 203:883–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ghiotto M, Gauthier L, Serriari N, Pastor
S, Truneh A, Nunès JA and Olive D: PD-L1 and PD-L2 differ in their
molecular mechanisms of interaction with PD-1. Int Immunol.
22:651–660. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng P and Zhou Z: Human cancer
immunotherapy with PD-1/PD-L1 blockade. Biomark Cancer. 7 (Suppl
2):S15–S18. 2015.
|
|
22
|
Catakovic K, Klieser E, Neureiter D and
Geisberger R: T cell exhaustion: From pathophysiological basics to
tumor immunotherapy. Cell Commun Signal. 15:12017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Palaga T, Miele L, Golde TE and Osborne
BA: TCR-mediated Notch signaling regulates proliferation and
IFN-gamma production in peripheral T cells. J Immunol.
171:3019–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Iwasaki M, Tanaka Y, Kobayashi H,
Murata-Hirai K, Miyabe H, Sugie T, Toi M and Minato N: Expression
and function of PD-1 in human γδ T cells that recognize
phosphoantigens. Eur J Immunol. 41:345–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang D, Lin J, Yang X, Long J, Bai Y, Yang
X, Mao Y, Sang X, Seery S and Zhao H: Combination regimens with
PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal
malignancies. J Hematol Oncol. 12:422019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Macian F: NFAT proteins: Key regulators of
T-cell development and function. Nat Rev Immunol. 5:472–484. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grievink HW, Luisman T, Kluft C, Moerland
M and Malone KE: Comparison of three isolation techniques for human
peripheral blood mononuclear cells: Cell recovery and viability,
population composition, and cell functionality. Biopreserv Biobank.
14:410–415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patsoukis N, Brown J, Petkova V, Liu F, Li
L and Boussiotis VA: Selective effects of PD-1 on Akt and Ras
pathways regulate molecular components of the cell cycle and
inhibit T cell proliferation. Sci Signal. 5:ra462012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vaeth M and Feske S: NFAT control of
immune function: New frontiers for an abiding trooper. F1000Res.
7:2602018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ponomarev V, Doubrovin M, Lyddane C,
Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S,
Blasberg R, et al: Imaging TCR-dependent NFAT-mediated T-cell
activation with positron emission tomography in vivo. Neoplasia.
3:480–488. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ding ZC, Lu XY, Yu M, Lemos H, Huang L,
Chandler P, Liu K, Walters M, Krasinski A, Mack M, et al:
Immunosuppressive myeloid cells induced by chemotherapy attenuate
antitumor CD4+ T-Cell Responses through the PD-1-PD-L1 Axis. Cancer
Res. 74:3441–3453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Medina PJ and Adams VR: PD-1 Pathway
Inhibitors: Immuno-oncology agents for restoring antitumor immune
responses. Pharmacotherapy. 36:317–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Y and Cao XT: Immunosuppressive cells
in tumor immune escape and metastasis. J Mol Med. 94:509–522. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dustin ML: The cellular context of T cell
signaling. Immunity. 30:482–492. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu X, Kim JL, Newcomb JR, Rose PE, Stover
DR, Toledo LM, Zhao H and Morgenstern KA: Structural analysis of
the lymphocyte-specific kinase Lck in complex with non-selective
and Src family selective kinase inhibitors. Structure. 7:651–661.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li M, Ong SS, Rajwa B, Thieu VT, Geahlen
RL and Harrison ML: The SH3 domain of Lck modulates T-cell
receptor-dependent activation of extracellular signal-regulated
kinase through activation of Raf-1. Mol Cell Biol. 28:630–641.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beyersdorf N, Kerkau T and Hunig T: CD28
co-stimulation in T-cell homeostasis: A recent perspective.
Immunotargets Ther. 4:111–122. 2015.PubMed/NCBI
|
|
40
|
Parry RV, Riley JL and Ward SG: Signalling
to suit function: Tailoring phosphoinositide 3-kinase during T-cell
activation. Trends Immunol. 28:161–168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Butler DE, Marlein C, Walker HF, Frame FM,
Mann VM, Simms MS, Davies BR, Collins AT and Maitland NJ:
Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and
compensatory Ras/Raf/MEK/ERK signalling in prostate cancer.
Oncotarget. 8:56698–56713. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Asati V, Mahapatra DK and Bharti SK:
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as
anticancer agents: Structural and pharmacological perspectives. Eur
J Med Chem. 109:314–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mahoney KM, Freeman GJ and McDermott DF:
The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in
melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hui E, Cheung J, Zhu J, Su X, Taylor MJ,
Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I and Vale RD: T
cell costimulatory receptor CD28 is a primary target for
PD-1-mediated inhibition. Science. 355:1428–1433. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jacquin-Porretaz C, Nardin C, Puzenat E,
Roche-Kubler B and Aubin F; Comité de suivi des effets secondaires
des immunothérapies anti-cancéreuses (CSESIAC), : Adverse effects
of immune checkpoint inhibitors used to treat melanoma and other
cancer. Presse Med. 46:808–817. 2017.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park JA and Cheung NV: Erratum to
‘limitations and opportunities for immune checkpoint inhibitors in
pediatric malignancies’ [Cancer Treat. Rev. 58C (2017) 22–33].
Cancer Treat Rev. 60:1582017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
McDermott DF and Atkins MB: PD-1 as a
potential target in cancer therapy. Cancer Med. 2:662–673.
2013.PubMed/NCBI
|
